About Halozyme
Halozyme is a company based in San Diego (United States) founded in 1999.. The company has 350 employees as of December 31, 2024. Halozyme has completed 2 acquisitions, including Antares Pharma and Elektrofi. Halozyme offers products and services including ENHANZE, Auto-Injector, and Multi-Dose Pen Technologies. Halozyme operates in a competitive market with competitors including Jazz Pharmaceuticals, Insulet, C4 Therapeutics, Erasca and MiRagen, among others.
- Headquarter San Diego, United States
- Employees 350 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Halozyme Therapeutics, Inc.
-
Annual Revenue
$1.02 B22.44as on Dec 31, 2024
-
Net Profit
$444.09 M57.71as on Dec 31, 2024
-
EBITDA
$632.79 M49.8as on Dec 31, 2024
-
Latest Funding Round
$625 M (USD), Post-IPO
Aug 15, 2022
-
Investors
SVB
& 4 more
-
Employee Count
350
as on Dec 31, 2024
-
Investments & Acquisitions
Antares Pharma
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Halozyme
Halozyme is a publicly listed company on the NASDAQ with ticker symbol HALO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Halozyme
Halozyme offers a comprehensive portfolio of products and services, including ENHANZE, Auto-Injector, and Multi-Dose Pen Technologies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enhances drug administration for better patient treatment efficacy.
Provides automatic injection solutions for simplified medication delivery.
Offers multi-dose systems to improve drug dosing accuracy and convenience.
Unlock access to complete
Leadership Team
35 people
Software Development Team
27 people
Sales and Marketing
22 people
Senior Team
14 people
Product Management Team
9 people
Human Resources and Administration
6 people
Specialty Team
6 people
Finance and Accounting
4 people
Unlock access to complete
Funding Insights of Halozyme
- Total Funding Total Funding
- Total Rounds 8
- Last Round Post-IPO — $625.0M
-
First Round
First Round
(06 Dec 2006)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2022 | Amount | Post-IPO - Halozyme | Valuation |
investors |
|
| Nov, 2019 | Amount | Post-IPO - Halozyme | Valuation |
investors |
|
| Jan, 2016 | Amount | Debt – Venture - Halozyme | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Halozyme
Halozyme has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include SVB, Oxford Finance and Athyrium Capital Management. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global private equity investments are managed by the firm.
|
Founded Year | Domain | Location | |
|
Venture debt firm focused on the life sciences sector
|
Founded Year | Domain | Location | |
|
Corporate-backed venture capital firm focused on the healthcare sector
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Halozyme
Halozyme has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Antares Pharma and Elektrofi. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Digital platform transforming the delivery of biologic medicines
|
2016 | ||||
|
Existing drugs are reformulated using proprietary pen injectors.
|
2000 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Halozyme
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Halozyme Comparisons
Competitors of Halozyme
Halozyme operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Insulet, C4 Therapeutics, Erasca and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Wearable insulin infusion systems are developed for diabetes patients.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Halozyme
Frequently Asked Questions about Halozyme
When was Halozyme founded?
Halozyme was founded in 1999 and raised its 1st funding round 7 years after it was founded.
Where is Halozyme located?
Halozyme is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of Halozyme?
Helen Torley is the current CEO of Halozyme.
How many employees does Halozyme have?
As of Dec 31, 2024, the latest employee count at Halozyme is 350.
What is the annual revenue of Halozyme?
Annual revenue of Halozyme is $1.02B as on Dec 31, 2024.
What does Halozyme do?
Halozyme was founded in 1999 and is headquartered in San Diego, United States. Operations focus on the biotechnology sector, where drug delivery technologies are developed to address various diseases. The lead product, ENHANZE, utilizes the proprietary enzyme rHuPH20 to enhance the delivery of injected drugs and fluids. Additionally, Hylenex, a recombinant endoglycosidase, is offered as an adjuvant to improve the dispersion and absorption of other injected drugs.
Who are the top competitors of Halozyme?
Halozyme's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Insulet.
What products or services does Halozyme offer?
Halozyme offers ENHANZE, Auto-Injector, and Multi-Dose Pen Technologies.
Is Halozyme publicly traded?
Yes, Halozyme is publicly traded on NASDAQ under the ticker symbol HALO.
How many acquisitions has Halozyme made?
Halozyme has made 2 acquisitions, including Antares Pharma, and Elektrofi.
Who are Halozyme's investors?
Halozyme has 5 investors. Key investors include SVB, Oxford Finance, Athyrium Capital Management, BioPharma Funds, and Roche.
What is Halozyme's ticker symbol?
The ticker symbol of Halozyme is HALO on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.